top of page

A novel multipotent sigma 1/M1 muscarinic activator for a comprehensive therapeutic strategy in AD

  • Writer: ANAVEX® Life Sciences Corp.
    ANAVEX® Life Sciences Corp.
  • Mar 26, 2014
  • 1 min read

International Geneva/Springfield Symposium on Advances in Alzheimer Therapy (2014), Geneva, Switzerland

A. Fisher, R. Medeiros, N. Bar-Ner, N. Natan, R. Brandeis, H. Elkon, V. Nahum, G. Grigoryan, M. Segal and F. Laferla


 
 
bottom of page